Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 1, 1996, Pages 91-98

  Walder, Claire E ^a   Errett, Carol J ^a   Bunting, Stuart ^a   Lindquist, Peter ^a   Ogez, John R ^a   Heinsohn, Henry G ^a   Ferrara, Napoleone ^a   Thomas, G Roger ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Hypoperfusion; Peripheral vascular disease

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIMB BLOOD FLOW; LIMB ISCHEMIA; MUSCLE BLOOD FLOW; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RABBIT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOOD FLOW VELOCITY; CHRONIC DISEASE; ENDOTHELIAL GROWTH FACTORS; HINDLIMB; ISCHEMIA; LYMPHOKINES; MALE; MUSCLE, SKELETAL; PERIPHERAL VASCULAR DISEASES; RABBITS; REGIONAL BLOOD FLOW; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030071236     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199601000-00015     Document Type: Article

References (37)

1. Widmer LK, Greensher A, Kannel WB. Occlusion of peripheral arteries: a study of 6400 working subjects. Circulation 1970;30:836-42.
2. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Cure 1983;6:87-91.
3. Graor RA, Gray BH. Interventional treatment of peripheral vascular disease. In: Young JR, Graor RA, Olin JW, Bartholomew JR. eds. Peripheral vascular diseases. St. Louis: Mosby Year Book, 1991:111-33.
4. Wakitani K, Takakuwa T, Sugioka M, Fujitani B, Aishita H. Inhibitory effect of OP-41483. α-CD. a prostacyclin analog. on peripheral vascular lesion models in rats. Jpn J Pharmacol 1992;59:57-63.
5. Dormandy J. Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia. Therapie 1991;46:319-22.
6. Krais T, Müller B. Iloprost in peripheral vascular disease. Cardiovasc Drug Rev 1991;9:158-71.
7. Creutzig A, Caspary L. Prostanoids in therapy of peripheral arterial occlusive disease. Therapie 1991;46:241-5.
8. Graor RA. Fibrinolysis and fibrinolytic therapy. In: Young JR, Graor RA, Olin JW, Bartholomew JR, eds. Peripheral vascular diseases. St. Louis: Mosby Year Book, 1991:93-110.
9. Bell WR, Bilazarian SD. Coagulation, coagulation disorders, and antithrombolytic therapy. In: Young JR, Graor RA, Olin JW, Bartholomew JR, eds. Peripheral vascular diseases. St. Louis: Mosby Year Book, 1991:71-91.
10. Pu L-Q, Sniderman AD, Brassard R, et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993;88:208-15.
11. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J. Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992;16:181-91.
12. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angio-genesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93:662-70.
13. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angio-genic mitogen. Science 1989;346:1306-9.
14. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1989;5:1806-14.
15. Tisher E, Mitchell R, Hartmann T, et al. The human gene for vascular endothelial growth factor. J Biol Chem 1991;266:11947-54.
16. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-9.
17. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-31.
18. Ploüet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO 1989;8:3801-7.
19. Conn G, Bayne M, Soderman L. Amino acid and cDNA sequence of a vascular endothelial cell mitogen homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990;87:2628-32.
20. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106-13.
21. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-43.
22. Banai S, Jaklitsch MT, Shou M. et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulanon 1994;89:2183-9.
23. Heymann MA, Payne BD, Hoffmann JIE, Rudolph AM. Blood flow measurements with nucleotide-labelled particles. Prog Cardiovasc Dis 1977;20:55-79.
24. Cameron HA, Waller PC, Ramsey LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 1988;26:569-76.
25. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-30.
26. Walder CE, Errett CJ, Bunting S, Lindquist P, Ferrara N, Thomas GR. Vascular endothelial growth factor (VEGF) improves blood flow and muscle function in a chronic ischemic limb model [Abstract]. FASEB J 1994;8:674.
27. Park JE, Keller G-A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential disposition into the subendothelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26.
28. de Vries C, Escobedo JA, Ueno H, Houck KA, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
29. Terman BI, Vermazen MD, Carrion ME. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992;34:1578-86.
30. Millauer B, Wizigmann-Voos S, Schnurch H. High affinity binding and developmental expression suggests Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-46.
31. Quinn T, Peters KG, de Vries C, Ferrara N, Williams LT. Fetal liver kinase is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993;90:7533-7.
32. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bio-availability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-7.
33. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993;3:244-50.
34. Asahara T, Takeshita S, Zheng LP, et al. Angiogenesis induced in vivo following site specific administration of vascular endothelial growth factor (VEGF) is potentiated by systemic administration of heparin [Abstract]. Proc Am Coll Cardiol 1994;23:338A.
35. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557-62.
36. Keski-Oja J, Raghow R, Sawdey M, et al. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-β. J Biol Chem 1988;263:3111-5.
37. Ammann AJ, Beck LS, DeGuzman L, et al. Transforming growth factor-β. Effect on soft tissue repair. Ann NY Acad Sci 1990;593:124-34.